Prof John Seymour
Honorary (Professorial Fellow)
Department of Medicine
1146 Scholarly works
9 Projects
HIGHLIGHTS
2023
Research grants (ARC, NHMRC, MRFF)
PRECISION\2013 Pharmacogenomic Medicines Optimisation for People With Cancer
2022
Journal article
Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy
DOI: 10.1182/blood.20220160402022
Journal article
Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance
DOI: 10.1182/bloodadvances.20220083252022
Journal article
Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL
DOI: 10.1182/blood.20210127752021
Journal article
Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition
DOI: 10.1182/bloodadvances.20210050832020
Research grants (other domestic)
Exercise Oncology Services Closer to Home: Improving Equity of Access and Survivor Outcome S Through the Development of a Multi-Disciplinary Digitally-Delivered Service.
2016
Research Grant
Circulating Tumour Dna to Monitor Treatment Response and Resistance in Chronic Lymphocytic Leukaemia
RECENT SCHOLARLY WORKS
2026
Journal article
Updated consensus guidelines for the diagnosis and management of patients with hairy cell leukemia (HCL) and HCL-variant.
DOI: 10.1182/blood.20250327572026
Journal article
Secondary outcomes of the TROG 99.03 randomized trial of systemic therapy after involved-field radiotherapy in early-stage follicular lymphoma, including toxicity, relapse and second malignancy data
DOI: 10.1016/j.radonc.2026.1113882026
Journal article
Impact of peri-transplant consolidative radiotherapy in patients with relapsed or refractory classical Hodgkin lymphoma.
DOI: 10.1080/10428194.2026.26311022026
Journal article
The landscape and evolution of clonal hematopoiesis in chronic lymphocytic leukemia
DOI: 10.1182/blood.20250299052026
Journal article
Venetoclax Retreatment in Chronic Lymphocytic Leukemia is biologically rational and clinically effective.
DOI: 10.1182/bloodadvances.20260198712026
Journal article
Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma
DOI: 10.1182/bloodadvances.20250166462026
Journal article
Transforming mantle cell lymphoma: the journey across eras.
DOI: 10.3324/haematol.2025.3002752026
Journal article
Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial
DOI: 10.1200/JCO-25-01695